ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.06 Billion KRW | 39.66% |
| 2022 | -5.08 Billion KRW | 77.49% |
| 2021 | -22.59 Billion KRW | -697.51% |
| 2020 | -2.83 Billion KRW | -158.21% |
| 2019 | 4.86 Billion KRW | 628.45% |
| 2018 | -921.08 Million KRW | -102.32% |
| 2017 | 39.7 Billion KRW | 21.48% |
| 2016 | 32.68 Billion KRW | -34.73% |
| 2015 | 50.08 Billion KRW | -12.66% |
| 2014 | 57.34 Billion KRW | 3.63% |
| 2013 | 55.33 Billion KRW | 1.59% |
| 2012 | 54.46 Billion KRW | 16.31% |
| 2011 | 46.82 Billion KRW | 652.31% |
| 2010 | 6.22 Billion KRW | -76.52% |
| 2009 | 26.5 Billion KRW | -11.6% |
| 2008 | 29.98 Billion KRW | -13.45% |
| 2007 | 34.64 Billion KRW | 49.59% |
| 2006 | 23.16 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.43 Billion KRW | 53.37% |
| 2023 Q4 | -3.06 Billion KRW | 38.67% |
| 2023 FY | -3.06 Billion KRW | 39.66% |
| 2023 Q1 | -5.33 Billion KRW | -4.82% |
| 2023 Q2 | -2.41 Billion KRW | 54.74% |
| 2023 Q3 | -5 Billion KRW | -107.41% |
| 2022 Q4 | -5.08 Billion KRW | -16.9% |
| 2022 Q1 | -15.83 Billion KRW | 0.0% |
| 2022 Q3 | -4.35 Billion KRW | -17.73% |
| 2022 Q2 | -3.69 Billion KRW | 76.66% |
| 2022 FY | -5.08 Billion KRW | 77.49% |
| 2021 Q2 | 2.92 Billion KRW | 16618.02% |
| 2021 FY | -22.59 Billion KRW | -697.51% |
| 2021 Q1 | -17.72 Million KRW | 99.37% |
| 2021 Q3 | -4.33 Billion KRW | -247.9% |
| 2020 Q1 | 4.88 Billion KRW | 0.28% |
| 2020 Q4 | -2.83 Billion KRW | -177.5% |
| 2020 Q3 | 3.65 Billion KRW | 66.97% |
| 2020 Q2 | 2.18 Billion KRW | -55.14% |
| 2020 FY | -2.83 Billion KRW | -158.21% |
| 2019 Q3 | 2.38 Billion KRW | 247.25% |
| 2019 Q1 | 1.4 Billion KRW | 252.5% |
| 2019 Q2 | -1.61 Billion KRW | -215.15% |
| 2019 FY | 4.86 Billion KRW | 628.45% |
| 2019 Q4 | 4.86 Billion KRW | 104.39% |
| 2018 Q3 | 40.77 Billion KRW | 98.83% |
| 2018 FY | -921.08 Million KRW | -102.32% |
| 2018 Q4 | -921.08 Million KRW | -102.26% |
| 2018 Q2 | 20.5 Billion KRW | -53.6% |
| 2018 Q1 | 44.19 Billion KRW | 11.29% |
| 2017 FY | 39.7 Billion KRW | 21.48% |
| 2017 Q1 | 25.77 Billion KRW | -21.14% |
| 2017 Q4 | 39.7 Billion KRW | 18.32% |
| 2017 Q2 | 30.23 Billion KRW | 17.27% |
| 2017 Q3 | 33.56 Billion KRW | 11.01% |
| 2016 Q2 | 35.38 Billion KRW | 16.86% |
| 2016 Q1 | 30.27 Billion KRW | -39.55% |
| 2016 Q4 | 32.68 Billion KRW | 9.5% |
| 2016 Q3 | 29.85 Billion KRW | -15.63% |
| 2016 FY | 32.68 Billion KRW | -34.73% |
| 2015 FY | 50.08 Billion KRW | -12.66% |
| 2015 Q1 | 33.2 Billion KRW | -42.09% |
| 2015 Q4 | 50.08 Billion KRW | 6.15% |
| 2015 Q2 | 41.56 Billion KRW | 25.17% |
| 2015 Q3 | 47.17 Billion KRW | 13.5% |
| 2014 FY | 57.34 Billion KRW | 3.63% |
| 2014 Q4 | 57.34 Billion KRW | 0.7% |
| 2014 Q1 | 53.61 Billion KRW | -3.1% |
| 2014 Q2 | 52.13 Billion KRW | -2.76% |
| 2014 Q3 | 56.94 Billion KRW | 9.23% |
| 2013 Q2 | 50.75 Billion KRW | -7.97% |
| 2013 FY | 55.33 Billion KRW | 1.59% |
| 2013 Q4 | 55.33 Billion KRW | 1.98% |
| 2013 Q3 | 54.26 Billion KRW | 6.92% |
| 2013 Q1 | 55.14 Billion KRW | 1.25% |
| 2012 FY | 54.46 Billion KRW | 16.31% |
| 2012 Q4 | 54.46 Billion KRW | 0.0% |
| 2011 FY | 46.82 Billion KRW | 652.31% |
| 2011 Q3 | 8.9 Billion KRW | -3.89% |
| 2011 Q2 | 9.26 Billion KRW | 137.3% |
| 2011 Q1 | 3.9 Billion KRW | 0.0% |
| 2010 Q2 | 23.81 Billion KRW | 5.5% |
| 2010 Q3 | -1.53 Billion KRW | -106.46% |
| 2010 FY | 6.22 Billion KRW | -76.52% |
| 2010 Q1 | 22.57 Billion KRW | 0.0% |
| 2009 Q2 | 14.55 Billion KRW | -30.59% |
| 2009 FY | 26.5 Billion KRW | -11.6% |
| 2009 Q3 | 20.34 Billion KRW | 39.82% |
| 2009 Q1 | 20.97 Billion KRW | 0.0% |
| 2008 Q2 | 14.43 Billion KRW | -38.76% |
| 2008 FY | 29.98 Billion KRW | -13.45% |
| 2008 Q3 | 18.1 Billion KRW | 25.43% |
| 2008 Q1 | 23.57 Billion KRW | 0.0% |
| 2007 Q2 | 23.02 Billion KRW | -82.42% |
| 2007 Q1 | 130.96 Billion KRW | 0.0% |
| 2007 Q3 | 23.24 Billion KRW | 0.94% |
| 2007 FY | 34.64 Billion KRW | 49.59% |
| 2006 FY | 23.16 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 100.278% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 100.455% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | 71.306% |
| Green Cross Corporation | 674.31 Billion KRW | 100.455% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | 138.133% |
| Celltrion, Inc. | 1325.8 Billion KRW | 100.231% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 100.199% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 97.117% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | 95.022% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 97.635% |